Melanocortin-4 receptor activation inhibits c-Jun N-terminal kinase activity and promotes insulin signaling.
Chai. Biaoxin B; Li. Ji-Yao JY; Zhang. Weizhen W; Wang. Hui H; Mulholland. Michael W MW
Key Findings
- MC4R activation by melanotan‑II blocks JNK activity in cells
- Reduced IRS‑1 ser307 phosphorylation and boosted AKT activation improve insulin signaling
- Melanotan‑II increased insulin‑driven glucose uptake in hypothalamic cells and raised AKT phosphorylation in rat hypothalamus
Practical Outcomes
- Melanotan‑II could be explored as a tool to enhance insulin signaling and metabolic health, but because the data are pre‑clinical, any use should be experimental, low‑dose, and closely monitored for blood‑sugar effects. More human studies are needed before it can be recommended as a reliable metabolic enhancer.
Summary
The study shows that activating the MC4R receptor with melanotan‑II (or similar compounds) can turn down a stress‑related pathway (JNK) and make insulin signals work better in cells and in the rat brain, leading to more glucose being taken up. This hints that melanotan‑II might help improve insulin sensitivity, but the evidence is still limited to lab dishes and animal brains, not real‑world human use.
Abstract
The melanocortin system is crucial to regulation of energy homeostasis. The melanocortin receptor type 4 (MC4R) modulates insulin signaling via effects on c-Jun N-terminal kinase (JNK). The melanocortin agonist NDP-MSH dose-dependently inhibited JNK activity in HEK293 cells stably expressing the human MC4R; effects were reversed by melanocortin receptor antagonist. NDP-MSH time- and dose-dependently inhibited IRS-1(ser307) phosphorylation, effects also reversed by a specific melanocortin receptor antagonist. NDP-MSH augmented insulin-stimulated AKT phosphorylation in vitro. The melanocortin agonist melanotan II increased insulin-stimulated AKT phosphorylation in the rat hypothalamus in vivo. NDP-MSH increased insulin-stimulated glucose uptake in hypothalamic GT1-1 cells. The current study shows that the melanocortinergic system interacts with insulin signaling via novel effects on JNK activity.
Study Information
pubmed
2009
2009-03-25T00:00:00.000Z
10.1016/j.peptides.2009.03.006
46
37